Items Tagged ‘BRAF V600E mutation’

September 24th, 2015

Zelboraf® Active in Hairy Cell Leukemia


The targeted agent, Zelboraf® (vemurafenib), which is approved for the treatment of melanoma, provided high anti-cancer activity among patients with hairy-cell leukemia that had stopped responding to prior therapies. These results were recently published in the New England Journal of Medicine. Hairy-cell leukemia is a type of cancer in which too many abnormal immune cells […]

View full entry

Tags: BRAF V600E mutation, Hairy Cell Leukemia, Leukemia, News, vemurafenib, zelboraf